Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Center LaboratoriesROCO:4123 +1.47%69 PB Ratio is 1.10 as of Jul. 21, 2026, which is 35% below its 10-year median of 1.68. GuruFocus rates ROCO:4123 with a GF Score™ of 69/100 and a GF Value™ of NT$43.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, Center Laboratories ranks better than 74.05% on this metric.
Center Laboratories Inc stock PB Ratio (=1.04) is close to 10-year low of 1.04.
The historical rank and industry rank for Center Laboratories's PB Ratio or its related term are showing as below:
ROCO:4123'
s PB Ratio Range Over the Past 10 Years
Min: 1.04 Med: 1.68 Max: 4.71
Current: 1.07
During the past 13 years, Center Laboratories's highest PB Ratio was 4.71. The lowest was 1.04. And the median was 1.68.
ROCO:4123's PB Ratio is ranked better than 74.05% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs ROCO:4123: 1.07
During the past 12 months, Center Laboratories's average Book Value Per Share Growth Rate was 48.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Center Laboratories was 41.70% per year. The lowest was -5.50% per year. And the median was 13.90% per year.
Back to Basics: PB Ratio
Center Laboratories (ROCO:4123) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Center Laboratories PB Ratio Related Terms
Center Laboratories PB Ratio Historical Data
* Premium members only.
The historical data trend for Center Laboratories's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Center Laboratories PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's PB Ratio distribution charts can be found below:
* The bar in red indicates where Center Laboratories's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Center Laboratories (ROCO:4123) has a PB Ratio of 1.10 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Center Laboratories and its competitors. This is 35% below median its historical median of 1.68. Over the past decade, Center Laboratories' PB Ratio has ranged from 1.04 to 4.71. According to the industry distribution chart, Center Laboratories ranks #239 out of 921 companies in the Drug Manufacturers industry, placing it in the top 26%.
Is Center Laboratories' PB Ratio too high?
Center Laboratories' current PB Ratio of 1.10 is 35% below median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 4.71. The Drug Manufacturers industry median PB Ratio is 1.86. Center Laboratories' value of 1.10 is 40.9% below this industry median. Based on the distribution chart, Center Laboratories ranks #239 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Center Laboratories has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Center Laboratories ranks #239 out of 921 companies for PB Ratio. This puts Center Laboratories in the upper half of its industry. The industry median PB Ratio is 1.86. Center Laboratories' value of 1.10 is 40.9% below this benchmark. Historically, Center Laboratories' own PB Ratio has ranged from 1.04 to 4.71 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 1.86, Center Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Center Laboratories's current PB Ratio of 1.10 is 40.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Center Laboratories and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Center Laboratories's current PB Ratio is 1.10, which is 35% below median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.04, compared to a current price of NT$38.05 — trading 11.6% below its estimated fair value. The current PB Ratio is 1.10, which is 35% below median its 10-year median of 1.68 and 40.9% below the Drug Manufacturers industry median of 1.86. Center Laboratories' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current PB Ratio is 1.10 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Center Laboratories (ROCO:4123) Overvalued in 2026?
Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued.
The current stock price of NT$38.05 is trading 11.6% below its estimated GF Value™ of NT$43.04.
GuruFocus considers Center Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4123:
PB Ratio: 1.10 (35% below median its 10-year median of 1.68)
GF Value™: NT$43.04 vs. price of NT$38.05 (11.6% below fair value)
Industry Position: 40.9% below the Drug Manufacturers median (#239 of 921)
No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
69GF Score
Get the complete analysis for ROCO:4123
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4123 has been successfully added to your 
